Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles
Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Vascular Medicine |
| Online Access: | http://dx.doi.org/10.1155/2013/548764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161227164024832 |
|---|---|
| author | Andrew W. Gardner Petar Alaupovic Donald E. Parker Polly S. Montgomery Omar L. Esponda Ana I. Casanegra |
| author_facet | Andrew W. Gardner Petar Alaupovic Donald E. Parker Polly S. Montgomery Omar L. Esponda Ana I. Casanegra |
| author_sort | Andrew W. Gardner |
| collection | DOAJ |
| description | Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670. |
| format | Article |
| id | doaj-art-fb9e78445c9a44bc8b20387cbcf8eaf7 |
| institution | OA Journals |
| issn | 2090-2824 2090-2832 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Vascular Medicine |
| spelling | doaj-art-fb9e78445c9a44bc8b20387cbcf8eaf72025-08-20T02:22:55ZengWileyInternational Journal of Vascular Medicine2090-28242090-28322013-01-01201310.1155/2013/548764548764Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein ProfilesAndrew W. Gardner0Petar Alaupovic1Donald E. Parker2Polly S. Montgomery3Omar L. Esponda4Ana I. Casanegra5Reynolds Oklahoma Center on Aging, Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK 73117, USAOklahoma Medical Research Foundation, Oklahoma City, OK 73104, USADepartment of Biostatistics and Epidemiology, OUHSC, Oklahoma City, OK 73117, USAReynolds Oklahoma Center on Aging, Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK 73117, USACardiovascular Section, Department of Medicine, OUHSC, Oklahoma City, OK 73117, USACardiovascular Section, Department of Medicine, OUHSC, Oklahoma City, OK 73117, USAApolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.http://dx.doi.org/10.1155/2013/548764 |
| spellingShingle | Andrew W. Gardner Petar Alaupovic Donald E. Parker Polly S. Montgomery Omar L. Esponda Ana I. Casanegra Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles International Journal of Vascular Medicine |
| title | Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles |
| title_full | Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles |
| title_fullStr | Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles |
| title_full_unstemmed | Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles |
| title_short | Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles |
| title_sort | influence of peripheral artery disease and statin therapy on apolipoprotein profiles |
| url | http://dx.doi.org/10.1155/2013/548764 |
| work_keys_str_mv | AT andrewwgardner influenceofperipheralarterydiseaseandstatintherapyonapolipoproteinprofiles AT petaralaupovic influenceofperipheralarterydiseaseandstatintherapyonapolipoproteinprofiles AT donaldeparker influenceofperipheralarterydiseaseandstatintherapyonapolipoproteinprofiles AT pollysmontgomery influenceofperipheralarterydiseaseandstatintherapyonapolipoproteinprofiles AT omarlesponda influenceofperipheralarterydiseaseandstatintherapyonapolipoproteinprofiles AT anaicasanegra influenceofperipheralarterydiseaseandstatintherapyonapolipoproteinprofiles |